Drug intelligence / Profile preview

EXOMETA

Development stage: Preclinical
Lead developer: Dermama Biotechnology
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

EXOMETA is an exosome-based therapy developed by Dermama Biotechnology, derived from human umbilical cord Wharton's Jelly (HUC-WJ) and endothelial progenitor cells. It is designed as a regenerative treatment for a broad range of conditions, including diabetic complications, stroke, neurodegenerative diseases, and chronic age-related disorders. The therapy functions by delivering a complex cargo of paracrine factors, including proteins and signaling molecules, to facilitate tissue repair and cellular regeneration without relying on a single defined molecular target. As a cell-derived product, it aims to leverage the natural regenerative potential of umbilical cord-derived vesicles to modulate inflammatory responses and promote neuroprotection.

Brand names: EXOMETA

Beyond the preview

Go deeper on EXOMETA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EXOMETA.

Explore the full profile